Moberg Pharma Yönetim

Yönetim kriter kontrolleri 1/4

Moberg Pharma CEO'su Anna Ljung, May2019 tarihinde atandı, in görev süresi 5.5 yıldır. in toplam yıllık tazminatı SEK 3.51M olup, şirket hissesi ve opsiyonları dahil olmak üzere 56.6% maaş ve 43.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.016% ine doğrudan sahiptir ve bu hisseler SEK 138.03K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 5.1 yıl ve 2 yıldır.

Anahtar bilgiler

Anna Ljung

İcra Kurulu Başkanı

SEK 3.5m

Toplam tazminat

CEO maaş yüzdesi	56.6%
CEO görev süresi	5.5yrs
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	5.1yrs
Yönetim Kurulu ortalama görev süresi	2yrs

Son yönetim güncellemeleri

Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year

May 08

Recent updates

We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely

Sep 14

Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year

May 08

CEO Tazminat Analizi

Anna Ljung'un ücretlendirmesi Moberg Pharma'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-SEK 18m
Jun 30 2024	n/a	n/a	-SEK 23m
Mar 31 2024	n/a	n/a	-SEK 23m
Dec 31 2023	SEK 4m	SEK 2m	-SEK 21m
Sep 30 2023	n/a	n/a	-SEK 18m
Jun 30 2023	n/a	n/a	-SEK 16m
Mar 31 2023	n/a	n/a	-SEK 16m
Dec 31 2022	SEK 3m	SEK 2m	-SEK 16m
Sep 30 2022	n/a	n/a	-SEK 17m
Jun 30 2022	n/a	n/a	-SEK 16m
Mar 31 2022	n/a	n/a	-SEK 16m
Dec 31 2021	SEK 2m	SEK 1m	-SEK 16m
Sep 30 2021	n/a	n/a	SEK 8m
Jun 30 2021	n/a	n/a	SEK 7m
Mar 31 2021	n/a	n/a	SEK 5m
Dec 31 2020	SEK 3m	SEK 2m	SEK 7m
Jun 30 2020	n/a	n/a	SEK 20m
Jun 30 2019	SEK 476k	SEK 151k	-SEK 8m

Tazminat ve Piyasa: Anna 'nin toplam tazminatı ($USD 319.33K ), Swedish pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 236.52K ).

Tazminat ve Kazançlar: Anna şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Anna Ljung (44 yo)

5.5yrs

Görev süresi

SEK 3,511,000

Tazminat

Ms. Anna Ljung, M.Sc. Econ., BA serves as Chairperson of Biosergen AB since June 14, 2024. She served as Chairman of The Board at OncoZenge AB (publ) until August 2023. She joined company since 2020.Ms. L...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Anna Ljung	Chief Executive Officer	5.5yrs	SEK 3.51m	0.016% SEK 138.0k
Marie Moberg	Co-Founder	18.7yrs	SEK 193.70k	Veri yok
Mark Beveridge	Vice President of Finance	5.1yrs	Veri yok	0.033% SEK 290.7k
Christina Erixon	Head of Pharmaceutical Development & Operations	less than a year	Veri yok	Veri yok
Amir Tavakkol	Chief Scientific Officer	no data	Veri yok	Veri yok
Gunilla Wengström	Senior Director of Sales & Marketing	5.8yrs	Veri yok	Veri yok
Anders Broijersen	Chief Medical Officer	2yrs	Veri yok	0.000020% SEK 174.7
Robert Ehrl	Head of Supply	less than a year	Veri yok	Veri yok

5.1yrs

Ortalama Görev Süresi

55.5yo

Ortalama Yaş

Deneyimli Yönetim: MOB 'un yönetim ekibi deneyimli ve deneyimlidir ( 5.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Howard Maibach	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Jonas Ekblom	Director	less than a year	Veri yok	Veri yok
Hakan Wallin	Independent Director	1.5yrs	SEK 99.00k	Veri yok
Nikolaj Sorensen	Independent Director	3.5yrs	SEK 170.00k	0.17% SEK 1.5m
Jan Faergemann	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Lennart Emtestam	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Johan Heilborn	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Bernt Lindelöf	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Kerstin Strinnholm	Independent Chairman of the Board	2.5yrs	SEK 360.00k	0.19% SEK 1.7m

2.0yrs

Ortalama Görev Süresi

60.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MOB 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Moberg Pharma Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Moberg Pharma AB (publ), Annual General Meeting, May 22, 2025

Independent Director recently bought kr144k worth of stock

Independent Chairman of the Board exercised options to buy kr397k worth of stock.

High number of new and inexperienced directors

Moberg Pharma AB (Publ) Elects Jonas Ekblom as Board Member

Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year

Recent updates

Consensus estimates of losses per share improve by 20%

Moberg Pharma AB (publ), Annual General Meeting, May 22, 2025

Moberg Pharma AB (publ) to Report First Half, 2025 Results on Aug 12, 2025

Moberg Pharma AB (publ) to Report Fiscal Year 2024 Results on Feb 11, 2025

We're Hopeful That Moberg Pharma (STO:MOB) Will Use Its Cash Wisely

New minor risk - Market cap size

Now 64% undervalued after recent price drop

Moberg Pharma AB (publ) Receives Information About Clinical Cure in a Subset of Patients in the Ongoing North American Phase 3 Study for MOB-015 Against Nail Fungus

Price target increased by 26% to kr29.00

Independent Director recently bought kr144k worth of stock

Independent Chairman of the Board exercised options to buy kr397k worth of stock.

High number of new and inexperienced directors

New major risk - Revenue and earnings growth

Now 22% undervalued

Moberg Pharma AB (Publ) Elects Jonas Ekblom as Board Member

Moberg Pharma AB (publ)'s (STO:MOB) CEO Will Probably Find It Hard To See A Huge Raise This Year

Moberg Pharma AB Announces MOB-015 Receives National Approvals for All Countries Included in the Decentralized Procedure

New major risk - Share price stability

Moberg Pharma (STO:MOB) Will Have To Spend Its Cash Wisely

Moberg Pharma Announces Leadership Changes

Moberg Pharma AB (publ) Appoints Nomination Committee

Moberg Pharma Completes Enrollment to the Phase 3 Study for Mob-015 in North America

New major risk - Shareholder dilution

Moberg Pharma AB (publ) Announces National Approval for MOB-015 in Sweden

Moberg Pharma AB (publ) to Report Fiscal Year 2023 Final Results on Apr 16, 2024

Moberg Pharma AB Announces That Mob-015 Has Receives National Approval in Ireland for the Treatment of Mild to Moderate Fungal Infections of the Nails in Adults

Moberg Pharma AB (publ) Announces Approval for Mob-015 in the European Union

New major risk - Market cap size

Moberg Pharma AB (Publ) Recommends for Approval in EU

High number of new and inexperienced directors

Moberg Pharma AB (Publ) Elects Håkan Wallin to the Board Members

Will Moberg Pharma (STO:MOB) Spend Its Cash Wisely?

Less than half of directors are independent

Moberg Pharma AB (publ) Appoints Anders Bröijersén as Chief Medical Officer and a Member of the Management Team

Moberg Pharma AB (publ), Annual General Meeting, May 16, 2023

Moberg Pharma AB (publ) Approves Board Appointments

Peter Wolpert and Fredrik Granström Step-Down from the Board

Moberg Pharma AB (Publ) Begins Patient Enrollment in North American Phase 3 Study

Moberg Pharma AB Announces Peter Wolpert and Fredrik Granström are Not Available for Re-Election

The Medical Products Agency in Sweden Will Be Reference Member State for Moberg Pharma's European Registration Application

Moberg Pharma AB Announces the Results from the North American Phase 3-Study with MOB-015 (topical terbinafine) for the Treatment of Onychomycosis

Moberg Pharma AB's Paid Subscription Units to Be Delisted

New 90-day low: kr6.40

Read This Before Selling Moberg Pharma AB (publ) (STO:MOB) Shares

New 90-day low: kr9.05

Market pulls back on stock over the past week

Moberg Pharma AB (publ) to Report Q1, 2021 Results on May 11, 2021

Moberg Pharma AB (publ) to Report Fiscal Year 2020 Results on Feb 09, 2021

Moberg Pharma AB (Publ) Appoints Nomination Committee

Moberg Pharma AB (publ), Annual General Meeting, May 18, 2021

New 90-day low: kr11.30

New 90-day low: kr13.52

Caret Pharma LLC entered into an agreement to acquire the assets of Fiber Choice® from Moberg Pharma AB (publ) (OM:MOB) for $6.7 million.

Moberg Pharma AB (publ)(OM:MOB) dropped from S&P Global BMI Index

New 90-day low - kr14.01

Earnings released

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş